ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Pharmacokinetics of APX001 Administered Intravenously

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02956499
Recruitment Status : Completed
First Posted : November 7, 2016
Last Update Posted : August 2, 2017
Sponsor:
Information provided by (Responsible Party):
Amplyx Pharmaceuticals

Brief Summary:
First In Human (FIH), randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) escalation study of approximately 80 subjects. The SAD portion of the study will enroll six cohorts of eight healthy subjects per cohort, for a total of approximately 48 healthy subjects. The MAD portion of the study will enroll four cohorts of eight healthy subjects per cohort, for a total of approximately 32 healthy subjects.

Condition or disease Intervention/treatment Phase
Fungal Infection Drug: APX001 single dose 1 Drug: APX001 single dose 2 Drug: APX001 single dose 3 Drug: APX001 single dose 4 Drug: APX001 single dose 5 Drug: APX001 single dose 6 Drug: APX001 multiple dose 1 Drug: APX001 multiple dose 2 Drug: APX001 multiple dose 3 Drug: APX001 multiple dose 4 Drug: Matching Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Actual Study Start Date : May 2016
Actual Primary Completion Date : July 2017
Actual Study Completion Date : July 2017

Arm Intervention/treatment
Experimental: Cohort 1
single intravenous dose
Drug: APX001 single dose 1
Drug: Matching Placebo
Experimental: Cohort 2
single intravenous dose
Drug: APX001 single dose 2
Drug: Matching Placebo
Experimental: Cohort 3
single intravenous dose
Drug: APX001 single dose 3
Drug: Matching Placebo
Experimental: Cohort 4
single intravenous dose
Drug: APX001 single dose 4
Drug: Matching Placebo
Experimental: Cohort 5
single intravenous dose
Drug: APX001 single dose 5
Drug: Matching Placebo
Experimental: Cohort 6
single intravenous dose
Drug: APX001 single dose 6
Drug: Matching Placebo
Experimental: Cohort 7
multiple intravenous doses
Drug: APX001 multiple dose 1
Drug: Matching Placebo
Experimental: Cohort 8
multiple intravenous doses
Drug: APX001 multiple dose 2
Drug: Matching Placebo
Experimental: Cohort 9
multiple intravenous doses
Drug: APX001 multiple dose 3
Drug: Matching Placebo
Experimental: Cohort 10
multiple intravenous doses
Drug: APX001 multiple dose 4
Drug: Matching Placebo



Primary Outcome Measures :
  1. Safety and tolerability of single and multiple doses of APX001 as measured by adverse events (AEs), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG). [ Time Frame: 21 days ]

Secondary Outcome Measures :
  1. Pharmacokinetics of single and multiple doses of APX001 as measured by maximum observed concentration (Cmax). [ Time Frame: 21 days ]
  2. Pharmacokinetics of single and multiple doses of APX001 as measured by area under the curve (AUC). [ Time Frame: 21 days ]
  3. Pharmacokinetics of single and multiple doses of APX001 as measured by terminal phase half-life (t1/2). [ Time Frame: 21 days ]
  4. Pharmacokinetics of single and multiple doses of APX001 as measured by volume of distribution (Vd). [ Time Frame: 21 days ]
  5. Pharmacokinetics of single and multiple doses of APX001 as measured by elimination rate constant (Kel). [ Time Frame: 21 days ]
  6. Pharmacokinetics of single and multiple dose of APX001 as measured by accumulation ratio. [ Time Frame: 21 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women of childbearing potential must agree to avoid pregnancy during the study and to use contraception at least 2 weeks before the start of the study until 3 months after the last dose of study drug.
  • Males with partner(s) of childbearing potential must agree to use appropriate barrier contraception from the screening period until 3 months after the last dose of study drug.
  • Screening hematology, clinical chemistry, coagulation and urinalysis consistent with overall good health.
  • No significantly abnormal findings on physical examination, ECG and vital signs.
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • Any uncontrolled or active major systemic disease including, but not limited to: cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with metastatic potential.
  • History or presence of malignancy within the past year. Subjects who have been successfully treated with no recurrence of basal cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.
  • Use of prescription medication within 14 days prior to the first dose of study drug and throughout the study.
  • Use of non-prescription or over-the-counter medications within 7 days prior to the first dose of study drug and throughout the study.
  • Positive results on any of the following Screening laboratory tests: serum pregnancy test, urine alcohol test, urine drugs of abuse, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02956499


Locations
Netherlands
PRA Health Sciences
Groningen, Netherlands
Sponsors and Collaborators
Amplyx Pharmaceuticals
Investigators
Study Director: Michael R Hodges, MD Amplyx Pharmaceuticals

Responsible Party: Amplyx Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02956499     History of Changes
Other Study ID Numbers: APX001-101
First Posted: November 7, 2016    Key Record Dates
Last Update Posted: August 2, 2017
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Mycoses